Evolent Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held on June 6, 2024. The filing details the voting outcomes for four proposals submitted to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting results.
Material Changes and Voting Results
Stockholders voted on four proposals with the following outcomes:
- Proposal 1 (Election of Directors): All ten nominees were elected. While all received majority support, significant "Against" votes were cast for three directors: Diane Holder (8,642,002 against), Peter Grua (3,909,853 against), and M. Bridget Duffy, MD (1,799,562 against).
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Proposal 3 (Say-on-Pay): Stockholders approved the compensation of named executive officers for 2023 on an advisory basis.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders selected a one-year frequency for future advisory votes on executive compensation. The Board has determined to hold these votes annually.
Guidance, Outlook, and Risks
The filing does not provide management guidance, financial outlook, risk factors, or contingencies. It strictly reports the administrative results of the annual meeting.
Key Facts for Investor Verification
- Verify the specific reasons for the elevated "Against" votes for directors Diane Holder, Peter Grua, and M. Bridget Duffy, which exceeded 3.5 million, 3.9 million, and 1.8 million votes respectively.
- Confirm the total number of shares represented at the meeting by aggregating For, Against, Abstentions, and Broker Non-Votes for Proposal 1.
- Note that the Board has committed to annual Say-on-Pay votes based on the shareholder selection in Proposal 4.